MYC and HSF1 Cooperate to Drive Sensitivity to Polo-like Kinase 1 Inhibitor Volasertib in High-grade Serous Ovarian Cancer

Files
Williams2025Cooperate-CCBY.pdf (23.18 MB)
Date
2025
Authors
Williams, Imade
O’Malley, Matthew
DeHart, Haddie
Walker, Bobby
Ulhaskumar, Vrushabh
Jothirajah, Pranav
Ray, Haimanti
Landrum, Lisa M.
Delaney, Joe R.
Nephew, Kenneth P.
Carpenter, Richard L.
Language
American English
Embargo Lift Date
Department
Obstetrics and Gynecology, School of Medicine
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
American Association for Cancer Research
Abstract

We show that HSF1 and MYC genes are co-amplified in more than 30% of HGSOC and demonstrate that HSF1 and MYC functionally cooperate to drive the growth of HGSOC cells. This work provides the foundation for HSF1 and MYC co-amplification as a biomarker for treatment efficacy of the polo-like kinase 1 inhibitor volasertib in HGSOC.

Description
Keywords
Cell cycle proteins, Heat shock transcription factors, Protein kinase inhibitors, Proto-oncogene proteins, Ovarian neoplasms
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Williams I, O'Malley M, DeHart H, et al. MYC and HSF1 Cooperate to Drive Sensitivity to Polo-like Kinase 1 Inhibitor Volasertib in High-grade Serous Ovarian Cancer. Cancer Res Commun. 2025;5(2):253-266. doi:10.1158/2767-9764.CRC-24-0400
ISSN
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
Cancer Research Communications
Rights
Attribution 4.0 International Creative Commons licenses
Source
PMC
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Permanent Link
https://hdl.handle.net/1805/46512
DOI
https://doi.org/10.1158/2767-9764.CRC-24-0400
Version
Final published version
Full Text Available at
This item is under embargo {{howLong}}
Collections
Open Access Policy Articles